SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics
INGN 6.670-0.1%10:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (789)7/11/2008 2:29:02 PM
From: tom popeRead Replies (1) of 802
 
There are a few summaries of the CC on Dew's thread, including this extract, verbatim, of course:

siliconinvestor.com

On meeting the primary, the IGNG science dude said multiple times "The primary endpoint was survival. Adevxin met the primary in the biomaker population". He read it carefully from notes every time. I guess if you intend to decieve, always stick to the lawryers aproved weasle words.

But the echange between the one skeptic caller and INGN was good for a laugh. Paraphrasing from memory:

Caller: Why did only half the patients have tissue samples collected?

Doc: "Because it can be difficult to get."

Caller: "So will this reduce the commercial value if you can not easily screen in the real world population?"

Somebody: "Oh know, it's easy to get the samples if you know it's important."

Caller: "Uh? Wouldn't a trial endpoint be considered important in a trial? Was this part of the primary?"

INGN: "Let us read our lawyers weasle words"

Caller (Interrupting): "No nead for that, I have your refuseal to answer in my notes already"

Caller: "Did the FDA place a number on how many patients must be available for the tissue analysis?"

Nance (near screaming): "Wrong!!!"

Caller (laughing): "How can a question be wrong"

Offstage, Nance to operator: "cut him off"
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News